Pearl covers the widest range of dental pathologies in a single FDA-cleared product. Retrace targets the treatment planning and case presentation side of dental AI, which is a different niche from the diagnostic imaging tools (Overjet, Pearl, VideaHealth) that dominate the dental AI conversation.
Pearl or Retrace: which should you choose?
- Multi-condition screening on bitewings and periapicals
- Case acceptance conversations with AI-annotated x-rays
- Practice-wide quality metrics via the analytics dashboard
- Generating treatment plans with AI assistance
- Presenting treatment options visually to patients
Pearl vs Retrace: FDA clearances, price and integrations side by side
| Pearl | Retrace | |
|---|---|---|
| Vendor | Pearl Inc. · Los Angeles, CA | Retrace |
| Category | Imaging & diagnostics | Practice management |
| FDA 510(k) | K250525 (Nov 14, 2025); K243234 (Jun 12, 2025); K243989 (May 23, 2025); K243230 (May 9, 2025); K243893 (May 5, 2025); K242600 (Apr 11, 2025); K242522 (Jan 16, 2025); K210365 (Mar 4, 2022) | None confirmed |
| Cleared for | Marks suspected caries, periapical radiolucency and impacted third molars on panoramic radiographs, patients 16 and older. / Second Opinion CS: detection and segmentation of caries on periapical radiographs, permanent teeth, patients 12 and older (second reader). / Second Opinion 3D: marks anatomy on CBCT (dentition, maxilla, mandible, inferior alveolar canal, sinus, airway). / Second Opinion BLE: bone-level measurements on bitewing and periapical radiographs, patients 12 and older. / Second Opinion Pediatric: caries detection on bitewing and periapical radiographs, patients 4 and older (primary or mixed dentition). / Periapical radiolucency detection with outlined regions on periapical radiographs, permanent teeth, patients 12 and older (second reader). / Second Opinion CC: caries detection with outlined regions on bitewing and periapical radiographs, patients 19 and older (second reader). / Second Opinion: detection of caries, calculus, periapical radiolucency and other findings on bitewing and periapical radiographs. | — |
| Imaging modalities | bitewing, periapical, CBCT | — |
| Pricing | Not published (Contact sales) | Not published (Contact sales) |
| Integrations | Eaglesoft, Dentrix, Open Dental, Curve Dental, Carestack | — |
| Best fit | group, dso | — |
| Last verified | Oct 22, 2026 | Oct 21, 2026 |
From each vendor's site and the FDA 510(k) database.
Strengths and limits
- Detects more pathology types than most competitors in a single analysis
- Widest PMS integration coverage, working with 5+ major systems
- Practice Intelligence adds business analytics on top of clinical detection
- Enterprise pricing model; cost unclear until sales conversation
- Detection accuracy is condition-dependent, strongest on caries, weaker on marginal bone loss
- Addresses the treatment planning and case presentation workflow rather than diagnostic imaging
- May complement diagnostic AI tools like Overjet, Pearl, or VideaHealth
- No confirmed FDA 510(k) clearance. Practices should verify regulatory status before clinical use
- Less publicly documented than established dental AI competitors
Next steps
Common questions
What is the difference between Pearl and Retrace?
Pearl covers the widest range of dental pathologies in a single FDA-cleared product. Retrace targets the treatment planning and case presentation side of dental AI, which is a different niche from the diagnostic imaging tools (Overjet, Pearl, VideaHealth) that dominate the dental AI conversation.
Which is FDA cleared, Pearl or Retrace?
Pearl: K250525, K243234, K243989, K243230, K243893, K242600, K242522, K210365. Retrace: no clearance confirmed. Check the scope of each clearance; features outside it are not cleared.